Literature DB >> 22414411

Damage control for intra-abdominal sepsis.

Brett H Waibel1, Michael F Rotondo.   

Abstract

With the success of damage-control surgery for the treatment of exsanguinating truncal trauma, it has been adapted to other surgical diseases associated with shock states, such as severe secondary peritonitis. The structured approach of damage control is easily adapted to and can incorporate the fundamental elements of the Surviving Sepsis Campaign. It is not meant to replace tried and true surgical principles, such as source control, but is a usable framework in managing the complicated circumstances seen with these patients. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22414411     DOI: 10.1016/j.suc.2012.01.006

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  8 in total

1.  Lessons from Trauma Care: Abdominal Compartment Syndrome and Damage Control Laparotomy in the Patient with Gastrointestinal Disease.

Authors:  Aaron Richman; Clay Cothren Burlew
Journal:  J Gastrointest Surg       Date:  2018-10-01       Impact factor: 3.452

2.  Therapeutic management of peritonitis: a comprehensive guide for intensivists.

Authors:  P Montravers; S Blot; G Dimopoulos; C Eckmann; P Eggimann; X Guirao; J A Paiva; G Sganga; J De Waele
Journal:  Intensive Care Med       Date:  2016-03-16       Impact factor: 17.440

3.  Using Machine Learning to Establish Predictors of Mortality in Patients Undergoing Laparotomy for Emergency General Surgical Conditions.

Authors:  Michelle T D Smith; John L Bruce; Damian L Clarke
Journal:  World J Surg       Date:  2021-10-26       Impact factor: 3.352

4.  Treatment strategy for hepatic trauma.

Authors:  Wu-Yong Yu; Qu-Jin Li; Jian-Ping Gong
Journal:  Chin J Traumatol       Date:  2016-06-01

5.  Management of the open abdomen using negative pressure wound therapy with instillation in severe abdominal sepsis: A review of 48 cases in Hospital Mexico, Costa Rica.

Authors:  Pablo Sibaja; Alfredo Sanchez; Guillermo Villegas; Alvaro Apestegui; Esteban Mora
Journal:  Int J Surg Case Rep       Date:  2016-11-17

Review 6.  2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation.

Authors:  Michele Pisano; Luigi Zorcolo; Cecilia Merli; Stefania Cimbanassi; Elia Poiasina; Marco Ceresoli; Ferdinando Agresta; Niccolò Allievi; Giovanni Bellanova; Federico Coccolini; Claudio Coy; Paola Fugazzola; Carlos Augusto Martinez; Giulia Montori; Ciro Paolillo; Thiago Josè Penachim; Bruno Pereira; Tarcisio Reis; Angelo Restivo; Joao Rezende-Neto; Massimo Sartelli; Massimo Valentino; Fikri M Abu-Zidan; Itamar Ashkenazi; Miklosh Bala; Osvaldo Chiara; Nicola De' Angelis; Simona Deidda; Belinda De Simone; Salomone Di Saverio; Elena Finotti; Inaba Kenji; Ernest Moore; Steven Wexner; Walter Biffl; Raul Coimbra; Angelo Guttadauro; Ari Leppäniemi; Ron Maier; Stefano Magnone; Alain Chicom Mefire; Andrew Peitzmann; Boris Sakakushev; Michael Sugrue; Pierluigi Viale; Dieter Weber; Jeffry Kashuk; Gustavo P Fraga; Ioran Kluger; Fausto Catena; Luca Ansaloni
Journal:  World J Emerg Surg       Date:  2018-08-13       Impact factor: 5.469

7.  Study of damage control strategy for non-traumatic diseases: a single-center observational study.

Authors:  Fumiko Nakamura; Rintaro Yui; Atsunori Onoe; Masanobu Kishimoto; Kazuhito Sakuramoto; Takashi Muroya; Kentaro Kajino; Hitoshi Ikegawa; Yasuyuki Kuwagata
Journal:  Eur J Med Res       Date:  2022-10-01       Impact factor: 4.981

8.  Efficacy and safety of active negative pressure peritoneal therapy for reducing the systemic inflammatory response after damage control laparotomy (the Intra-peritoneal Vacuum Trial): study protocol for a randomized controlled trial.

Authors:  Derek J Roberts; Craig N Jenne; Chad G Ball; Corina Tiruta; Caroline Léger; Zhengwen Xiao; Peter D Faris; Paul B McBeth; Christopher J Doig; Christine R Skinner; Stacy G Ruddell; Paul Kubes; Andrew W Kirkpatrick
Journal:  Trials       Date:  2013-05-16       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.